# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0000000000-23-001784
**Filing Date:** 2023-2
**Character Count:** 4845
**Document Hash:** fb51aaa252a7d59aa799a14e685c5b54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001784.hdr.sgml**: 20231011

**ACCESSION NUMBER**: 0000000000-23-001784

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230222

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001829126-22-020607

## Text-Extract

```

United States securities and exchange commission logo

                            February 22, 2023

       Ian Bothwell
       CFO
       Skycrest Holdings, LLC
       1930 Harrison Street, Suite 204
       Hollywood, FL 33020

                                                        Re: Organicell
Regenerative Medicine, Inc.
                                                            Schedule 13D/A
filed by Skycrest Holdings, LLC
                                                            Filed February 14,
2023
                                                            File No. 005-87575

       Dear Ian Bothwell:

               We have reviewed the above-captioned filing and February 14,
2023 response to our
       comment letter and have the following comment. Unless we note otherwise,
our references to
       prior comments are to comments in our January 20, 2023 letter.

       Schedule 13D/A filed February 14, 2023

       General

   1.                                                   We note your response
to comment 2. The amended filing does not provide the required
                                                        qualitative disclosure
narrative for each item requirement of Schedule 13D, including any
                                                        negative responses. See
Rule 13d-1(a) and Instruction A. to Schedule 13D. While the
                                                        staff of the Office of
Mergers and Acquisitions will not undertake any further examination
                                                        of the filer's
non-compliance with this rule at this time, we reserve the right to make
                                                        further inquiry into
this matter and make any recommendations we deem appropriate.
             Please direct any questions to Michael Killoy (202) 551-7576 or
Nicholas Panos at (202)
       551-3266.

                            Sincerely,

                            Division of Corporation Finance

                            Office of Mergers & Acquisitions
       cc:                                              Edward Anderson

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 22, 2023

Ian Bothwell
CFO
Skycrest Holdings, LLC
1930 Harrison Street, Suite 204
Hollywood, FL 33020

Re: Organicell Regenerative Medicine, Inc.
Schedule 13D/A filed by Skycrest Holdings, LLC
Filed February 14, 2023
File No. 005-87575

Dear Ian Bothwell:

We have reviewed the above-captioned filing and February 14, 2023 response to our comment letter and have the following comment. Unless we note otherwise, our references to prior comments are to comments in our January 20, 2023 letter.

Schedule 13D/A filed February 14, 2023

General

1. We note your response to comment 2. The amended filing does not provide the required qualitative disclosure narrative for each item requirement of Schedule 13D, including any negative responses. See Rule 13d-1(a) and Instruction A. to Schedule 13D. While the staff of the Office of Mergers and Acquisitions will not undertake any further examination of the filer's non-compliance with this rule at this time, we reserve the right to make further inquiry into this matter and make any recommendations we deem appropriate.

Please direct any questions to Michael Killoy (202) 551-7576 or Nicholas Panos at (202) 551-3266.

Sincerely,

Division of Corporation Finance
Office of Mergers & Acquisitions

cc: Edward Anderson